Skip to main content
. 2018 Sep 24;128(11):4970–4979. doi: 10.1172/JCI99261

Figure 5. Prophylactic administration of IL-22 reduces GVHD.

Figure 5

B6D2F1 mice received PBS or IL-22 injections from day +1 after BMT from B6 donors (GVHD, +) or B6D2F1 donors (No GVHD, –). (A and B) Clinical GVHD score (A) and survival (B) of mice after BMT (GVHD +: PBS, black circles, n = 18; IL-22, blue circles, n = 16; GVHD –, white circles, n = 7). (C−E) Samples were analyzed on day +7 after BMT. (C) Serum REG3γ levels. (D) Ileal tissue Reg3g mRNA expression. *P < 0.05, **P < 0.01, unpaired 2-tailed t test (A), 1-way ANOVA (C and D); *P < 0.05, log-rank test (B). (E) H&E (top) staining and REG3γ (bottom) staining by immunohistochemistry in ileum from individual mice with or without IL-22 treatment. Naive B6D2F1 mice were used as controls. Images were taken with an Olympus BX51 with a ×20 objective. Scale bars: 100 μm. Data are expressed as mean ± SEM.